13F Holdings
中文EN

PPBT PURPLE BIOTECH LTD. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1614744 · Fiscal year ends 12/31

Financial factors as of 2020-12-31 (FY2020), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY0.0%
TTM net income YoY378.6%
TTM EPS YoY181.3%
Revenue 3-yr CAGR115.4%
Net income 3-yr CAGR32.0%

Margins

Gross margin—
Operating margin-1,261.2%
Net margin2,799.9%
FCF margin154.9%
EBITDA margin—

Returns

ROE62.4%
ROA56.8%
ROIC (approx.)-26.9%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets4.8%
Debt / equity0.00x
Current ratio19.14x
Interest coverage-206.75x

Cash quality & payout

Operating cash flow / net income0.06x
Accruals ratio53.4%
Payout ratio—
Capex / revenue15.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$3.73M$7.62M$17.03M$16.32M$11.83M
SG&A expense$3.25M$3.18M$5.24M$6.28M$6.11M
Operating income——-$22.27M-$22.60M-$17.93M
Interest expense$982,000$483,000$2.19M$67,000-$212,000
Net income-$26.39M-$7.24M-$19.88M-$21.67M$18.38M
EPS (basic)0.034.4417.9623.9717,568,036.00
EPS (diluted)0.034.9917.9623.9717,568,036.00
Weighted avg. shares (diluted)480,0531.64M1.11M904,054—
Balance sheet
Cash & equivalents$8.72M$7.40M$14.49M$15.03M$10.89M
Short-term investments—$275,000$73,000$431,000$36.31M
Receivables———$431,000—
Current assets$9.87M$8.91M$15.79M$33.26M$48.47M
PP&E, netmay include right-of-use assets (IFRS)$124,000$124,000$154,000$215,000$277,000
Intangibles$7.36M$27.84M$28.04M$20.68M$20.48M
Total assets$17.57M$37.04M$44.30M$54.62M$70.20M
Current liabilities$7.75M$3.99M$9.70M$7.06M$4.25M
Total liabilities$7.91M$4.13M$10.01M$7.52M$5.09M
Shareholders' equity$9.71M$32.86M$34.21M$46.91M$64.83M
Cash flow statement
Operating cash flow-$5.66M-$14.37M-$19.93M-$16.73M-$374,000
Capital expenditure$3,000—$3,000$26,000$115,000
Free cash flow-$5.66M—-$19.93M-$16.76M-$489,000
Investing cash flow$632,000$509,000$13.88M$19.91M$13.41M
Financing cash flow$6.33M$6.77M$5.45M$1.11M—
Stock-based compensation$309,000$582,000$1.88M$2.41M$2.08M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.